About SENTI BIOSCIENCES, INC.
Senti Bio is a clinical-stage company developing a new generation of cell and gene therapies for patients with incurable diseases using synthetic biology to engineer Gene Circuits for enhanced precision and control. Their lead product candidate, SENTI-202, is in clinical trials for acute myeloid leukemia.
Development of cell and gene therapies using synthetic biologyEngineering of Gene Circuits for enhanced precision and control in targeting cancer cellsPipeline of cell therapies targeting difficult-to-treat liquid and solid tumorsAbility to use both NK and T cells for different indications
Recent Federal Awards
| Award | Agency | Amount | Date |
|---|---|---|---|
| Federal contract award | Department of Health and Human Services | $2.0M |
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to SENTI BIOSCIENCES, INC. right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.